(Source: Actelion Ltd) Phase III study TOMORROW aims to show the long-term benefits of macitentan (Opsumit) in children with pulmonary arterial hypertension (PAH) Global program has received endorsement from the US FDA (through a pediatric Written Request) and in the EU (through a Paediatric Investigation Plan) ALLSCHWIL/BASEL, SWITZERLAND - 06 July 2016 - Actelion Ltd (SIX: ATLN) announced today that it will be initiating a Phase III study to evaluate the effect of macitentan on delaying disease progression in children with PAH using a pediatric formulation of macitentan (Opsumit). TOMORROW (pediaTric use Of Macitentan tO delay disease pRogRessiOn in PAH Worldwide) is a multicenter,...
↧